Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 2, 1996, Pages 403-415

  Krossnes, Bård Kronen ^a,b,c   Mella, Olav ^a   Dahl, Olav ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Kreftforeningen   (Norway)

Author keywords

Glioma; Hyperthermia; Nitroprusside

Indexed keywords

FENTANYL; FLUANISONE; MIDAZOLAM; NITROPRUSSIDE SODIUM; PENTOBARBITAL;

ANESTHESIA; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; HEART RATE; HYPERTHERMIC THERAPY; INDUCED HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; TEMPERATURE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VOLUME;

EID: 0030250002     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00210-6     Document Type: Article

References (40)

1. 1. Acker, B.; Lentle, B.; Chaplin, D. J. The effect of hydralazine (apresoline) on blood flow in human tumours. In: Fielden, E. M.; Fowler, J. F.; Hendry, J. H.; Scott, D., eds. Proceedings of the 8th International Congress on Radiation Research. Vol. 1. London: Taylor and Francis; 1987:297.
2. 2. Berne, R. M.; Levy, M. N. Cardiovascular Physiology. St. Louis: Mosby; 1967.
3. 3. Bjerkvig, R.; Lærum, O. D.; Mella, O. Glioma cell interactions with fetal rat brain aggregates in vitro and with brain tissue in vivo. Cancer Res. 46:4071-4079; 1986.
4. 4. Chaplin, D. J.; Trotter, M. J. Chemical modifiers of tumor blood flow. In: Vaupel, P.; Jain, R. K., eds. Tumor blood supply and metabolic microenvironment. Stuttgart: Gustav Fischer Verlag; 1991:65-85.
5. 5. Corkill, G.; Hodgson, M. J. H. Hypotension with sodium nitroprusside in the surgery of cerebral aneurysms. Anaesthesia 28:191-194; 1973.
6. 6. Dewhirst, M. W.; Prescott, D. M.; Clegg, S.; Samulski, T. V.; Page, R. L.; Thrall, D. E.; Leopold, K.; Rosner, G.; Acker, J. C.; Oleson, J. R. The use of hydralazine to manipulate tumour temperatures during hyperthermia. Int. J. Hyperthermia 6(6):971-983; 1990.
7. 7. Dewhirst, M. W.; Sim, D. A.; Sapareto, S.; Connor, W. G. Importance of minimum tumor temperature in determining early and long-term responses of spontaneous canine and feline tumors to heat and radiation. Cancer Res. 44:43-50; 1984.
8. 8. Garg, U. C.; Devi, L.; Turndorf, H.; Goldfrank, L. R.; Bansinath, M. Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells. Brain Res. 592:208-212; 1992.
9. 9. Gerweck, L. E. Modification of cell lethality at elevated temperatures: The pH-effect. Radiat. Res. 70:224-235; 1977.
10. 10. Gilman, A. G.; Goodman, L. S.; Rall, T. W.; Murad, F. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985.
11. 11. Guyton, A. C. Textbook of Medical Physiology. 8th ed. Philadelphia PA: W. B. Saunders Company; 1991.
12. 12. Hasegawa, T.; Song, C. W. Effect of hydralazine on the blood flow in tumors and normal tissues in rats. Int. J. Radiat. Oncol. Biol. Phys. 20:1001-1007; 1991.
13. 13. Honess, D. J.; Hu, D. E.; Bleehen, N. M. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. Int. J. Hyperthermia 7(4):667-679; 1991.
14. 14. Horsman, M. R.; Christensen, K. L.; Overgaard, J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int. J. Hyperthermia 5(2):123-136; 1989.
15. 15. Ioannidis, I.; de Groot, H. Cytotoxicity of nitric oxide in Fu5 rat hepatoma cells: Evidence for co-operative action with hydrogen peroxide. Biochem. J. 296:341-345; 1993.
16. 16. Jirtle, R. L. Chemical modification of tumour blood flow. Int. J. Hyperthermia 4(4):355-371; 1988.
17. 17. Johnson, R.; Fowler, J. F.; Zanelli, G. D. Changes in mouse blood pressure, tumor blood flow, and core and tumor temperatures following Nembutal or Urethane anesthesia. Radiology 118:697-703; 1976.
18. 18. Kalmus, J.; Okunieff, P.; Vaupel, P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors. Cancer Res. 50:15-19; 1990.
19. 19. Lee, Y. S.; Wurster, R. D. Potentiation of anti-proliferative effect of nitroprusside by ascorbate in human brain tumor cells. Cancer Lett. 78:19-23; 1994.
20. 20. Lærum, O. D.; Rajewsky, M. F.; Schachner, M.; Stravrou, D.; Haglid, K. G.; Haugen, Å. Phenotypic properties of neoplastic cell lines developed from fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. Z. Krebsforschung 89:273-295; 1977.
21. 4An tumours. Effects of a single or two equal fractions at different intervals. In Vivo 2:307-312; 1988.
22. 22. Menke, H.; Vaupel, P. Effect of injectable or inhalational anesthetics and of neuroleptic, neuroleptanalgesic, and sedative agents on tumor blood flow. Radiat. Res. 114:64-76; 1988.
23. 23. Öberg, B. Overall cardiovascular regulation. Annu. Rev. Physiol. 38:537-570; 1976.
24. 24. Okunieff, P.; Walsh, C. S.; Vaupel, P.; Kallinowski, F.; Hitzig, B. M.; Neuringer, L. J.; Suit, H. D. Effects of hydralazine on in vivo tumor energy metabolism, hematopoietic radiation sensitivity, and cardiovascular parameters. Int. J. Radiat. Oncol. Biol. Phys. 16:1145-1148; 1989.
25. 25. Omvik, P.; Tarazi, R. C.; Bravo, E. L. Regulation of sodium balance in hypertension. Hypertension 2:515-523; 1980.
26. 26. Overgaard, J. Influence of extracellular pH on the viability and morphology of tumor cells exposed to hyperthermia. J. Natl. Cancer Inst. 56:1243-1250; 1976.
27. 27. Pallavicini, M. G.; Hill, R. P. Effect of tumor blood flow manipulations on radiation response. Int. J. Radiat. Oncol. Biol. Phys. 9:1321-1325; 1983.
28. 28. Prescott, D. M.; Samulski, T. V.; Dewhirst, M. W.; Page, R. L.; Thrall, D. E.; Dodge, R. K.; Oleson, J. R. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int. J. Radiat. Oncol. Biol. Phys. 23:377-385; 1992.
29. 29. Schulz, V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin. Pharmacokinet. 9:239-251; 1984.
30. 30. Shah, N.; Del Valle, O.; Edmondson, R.; Acampora, G.; Dwyer, D.; Matarazzo, D.; Rogatko, A.; Thorne, A.; Bedford, R. F. Esmolol infusion during nitroprusside-induced hypotension: Impact on hemodynamics, ventricular performance, and venous admixture. J. Cardiothorac. Vasc. Anesth. 6(2):196-200; 1992.
31. 31. Shipley, R. E.; Study, R. S. Changes in renal blood flow, extraction of inulin, glomerular titration rate, tissue pressure and urine flow with acute alterations of renal artery blood pressure. Am. J. Physiol. 167:676-688; 1951.
32. 32. Skolleborg, K. C.; Grönbech, J. E.; Grong, K.; Åbyholm, F. E.; Lekven, J. Distribution of cardiac output during pentobarbital vs. midazolam/fentanyl/fluanisone anaesthesia in the rat. Lab. Anim. 24:221-227; 1990.
33. 33. Styles, M.; Coleman, A. J.; Leary, W. P. Some hemodynamic effects of sodium nitroprusside. Anesthesiology 38(2):173-176; 1973.
34. 34. Taylor, T. H.; Styles, M.; Lamming, A. J. Sodium nitroprusside as a hypotensive agent in general anaesthesia. Br. J. Anaesth. 42:859-864; 1970.
35. 35. Thurau, K.; Wober, E. Zur Lokalisation der autoregulativen Widerstandsänderungen in der Niere. Pflügers Arch. Physiol. 274:553-566; 1962.
36. 36. Tinker, J. H.; Michenfelder, J. D. Sodium nitroprusside: Pharmacology, toxicology and therapeutics. Anesthesiology 45(3):340-354; 1976.
37. 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension. Br. J. Cancer 62:553-560; 1990.
38. 38. Voorhees, W. D., III; Babbs, C. F. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur. J. Cancer Clin. Oncol. 18(10):1027-1033; 1982.
39. 39. Walker, H. J.; Geriton, D. J. Vasodilator therapy and the anesthetist: A review of nitroprusside, labetolol, hydralazine and nitroglycerin. J. Am. Assoc. Nurse Anesthet. 57(5):435-444; 1989.
40. 40. Zanelli, G. D.; Lucas, P. B.; Fowler, J. F. The effect of anaesthetics on blood perfusion in transplanted mouse tumours. Br. J. Cancer 32:380-390; 1975.